[Migraine prophylaxis-all just antibodies? : Medical and nonmedical migraine preventive treatment in times of CGRP antibodies]. / Migräneprophylaxe alles nur noch Antikörper? : Medikamentöse und nicht-medikamentöse Migräneprophylaxe in Zeiten der CGRP-Antikörper.
Schmerz
; 34(6): 476-485, 2020 Dec.
Article
em De
| MEDLINE
| ID: mdl-32945948
ABSTRACT
BACKGROUND:
Migraine is a frequently underdiagnosed disease that is associated with a high burden on affected patients. There are a variety of prophylactic treatment options available, that have been expanded with the introduction of the CGRP-(receptor-)antibodies.OBJECTIVES:
Status of pharmacologic and nonpharmacologic preventive treatment in migraine therapy.METHODS:
Analysis and evaluation of internationally published articles concerning preventive treatment of episodic and chronic migraine.RESULTS:
There are many approved medications for migraine prophylaxis with different evidence. The possibilities were further expanded with CGRP antibodies. Comparative studies of the new antibodies with previous prophylactic drugs have not yet been published, so it's unclear whether the antibodies are therapeutically superior. What should be emphasized is their rapid onset of action and their good tolerance. Basically, an individual choice of prophylaxis, which is based on affectedness, comorbidities and comedication, makes sense. In addition, a combination with nondrug measures is always mandatory.CONCLUSIONS:
A variety of medicinal and non-medicinal measures are available for the treatment of migraine, which should be used multimodally.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peptídeo Relacionado com Gene de Calcitonina
/
Transtornos de Enxaqueca
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
De
Revista:
Schmerz
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2020
Tipo de documento:
Article